David A. Santos - 17 Jun 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: RIGL
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2026, 16:11:57 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Raymond Furey (Attorney-in-Fact)

Key filing fact

David A. Santos filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 22 Jun 2026.

Key facts

This page summarizes David A. Santos's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2026, 16:11.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001820066 Primary reporting owner

Santos David A

Relationship: EVP, Chief Commercial Officer
Address: RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Signature date: 22 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RIGL transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +7,394
Change %
Price: $0.000000^*
Shares after: 7,394
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,394
Exercise price: $22.49
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

Footnote F2

The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.